Monitor for upcoming earnings or pipeline updates; such concentrated C-suite selling often precedes negative news or reflects valuation concerns. Watch for follow-on selling or lack of buybacks.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 16 $28.29entry
- T+1 · 8mo ago +2.33%α +2.07% · $28.95
- T+5 · 8mo ago −8.31%α −6.27% · $25.94
- T+20 · 7mo ago +39.94%α +36.14% · $39.59
- T+60 · 5mo ago +40.30%α +31.87% · $39.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Centessa Pharmaceuticals C-suite executives sold over $7.2M in stock within a week, primarily from Chief People Officer Karen Anderson's open-market sales of 215,922 shares. These sales followed derivative exercises and represent a material insider divestment.
Key Financial Metrics
Key Facts
- Chief People Officer Karen Anderson sold 215,922 shares for $5.65M in open-market transactions at ~$26.15 per share
- Anderson also exercised derivatives for 407,244 shares (some at $4.01, others at $0), with total economic value of $816,524.22
- Chief Business Officer Gregory Weinhoff sold 61,253 shares for $1.6M
- Total open-market sales by insiders: $7.25M over 7 days
- Total insider sales represent ~0.19% of $3.8B market cap, significant for a biotech
Financial Impact
$7.25M in open-market insider selling, representing 0.19% of market cap
Risk Factors
- Insider selling may signal lack of confidence in near-term prospects
- Biotech stocks are sensitive to sentiment; this level of selling could pressure share price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (7 trades, 7d window) | cluster-CNTA-1773699014839 |
Track record
5 reports on CNTA
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +8.31% at T+5 after the Mar 13, 2026 report. 3 of 3 went positive at some point.
Filters
- Jul 6, 202619w ago 15-12G Bearish 7/10 No price data
- Apr 17, 202630w ago PREM14A Bullish 9/10 Entry $39.51 to $39.51 · 0.00% −0.91% vs SPY
- Apr 13, 202631w ago DEFA14A Bullish 8/10 Entry $39.59 to $39.49 ▼ −0.25% −1.65% vs SPY
- Mar 13, 202635w ago Insider Cluster Bearish 7/10 Viewing Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
- Mar 13, 202635w ago Insider Cluster Bearish 6/10 Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers